Scotia Capital’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.53M | Buy |
129,510
+71,528
| +123% | +$3.88M | 0.02% | 292 |
|
|
2026
Q1 | $3.64M | Buy |
57,982
+5,508
| +10% | +$441K | 0.02% | 348 |
|
|
2025
Q4 | $5M | Buy |
52,474
+36,791
| +235% | +$3.61M | 0.02% | 306 |
|
|
2025
Q3 | $1.53M | Buy |
15,683
+590
| +4% | +$61.1K | 0.01% | 495 |
|
|
2025
Q2 | $1.62M | Buy |
15,093
+104
| +0.7% | +$10.5K | 0.01% | 451 |
|
|
2025
Q1 | $1.51M | Sell |
14,989
-805
| -5% | -$81.1K | 0.01% | 443 |
|
|
2024
Q4 | $1.41M | Buy |
15,794
+34
| +0.2% | +$2.99K | 0.01% | 458 |
|
|
2024
Q3 | $1.32M | Sell |
15,760
-22
| -0.1% | -$1.73K | 0.01% | 457 |
|
|
2024
Q2 | $1.22M | Buy |
15,782
+9
| +0.1% | +$659 | 0.01% | 462 |
|
|
2024
Q1 | $1.08M | Sell |
15,773
-1,248
| -7% | -$80.2K | 0.01% | 482 |
|
|
2023
Q4 | $984K | Buy |
17,021
+7,014
| +70% | +$374K | 0.01% | 455 |
|
|
2023
Q3 | $528K | Sell |
10,007
-13
| -0.1% | -$682 | ﹤0.01% | 550 |
|
|
2023
Q2 | $542K | Hold |
10,020
| – | – | ﹤0.01% | 541 |
|
|
2023
Q1 | $501K | Sell |
10,020
-1,405
| -12% | -$66.2K | ﹤0.01% | 545 |
|
|
2022
Q4 | $529K | Sell |
11,425
-4,335
| -28% | -$188K | ﹤0.01% | 549 |
|
|
2022
Q3 | $610K | Buy |
15,760
+1,295
| +9% | +$52K | ﹤0.01% | 528 |
|
|
2022
Q2 | $539K | Sell |
14,465
-820
| -5% | -$33.4K | ﹤0.01% | 561 |
|
|
2022
Q1 | $677K | Buy |
15,285
+4,183
| +38% | +$181K | ﹤0.01% | 579 |
|
|
2021
Q4 | $472K | Sell |
11,102
-50
| -0.4% | -$2.1K | ﹤0.01% | 641 |
|
|
2021
Q3 | $484K | Sell |
11,152
-8,515
| -43% | -$377K | ﹤0.01% | 628 |
|
|
2021
Q2 | $841K | Hold |
19,667
| – | – | 0.01% | 541 |
|
|
2021
Q1 | $760K | Buy |
19,667
+4,118
| +26% | +$156K | 0.01% | 539 |
|
|
2020
Q4 | $559K | Buy |
15,549
+4,531
| +41% | +$163K | 0.01% | 549 |
|
|
2020
Q3 | $421K | Buy |
+11,018
| New | +$425K | ﹤0.01% | 536 |
|
|
2020
Q1 | – | Sell |
-23,811
| Closed | -$1.08M | – | 651 |
|
|
2019
Q4 | $1.08M | Sell |
23,811
-31,396
| -57% | -$1.31M | 0.01% | 383 |
|
|
2019
Q3 | $2.25M | Buy |
55,207
+4,930
| +10% | +$209K | 0.03% | 264 |
|
|
2019
Q2 | $2.16M | Buy |
50,277
+38,470
| +326% | +$1.48M | 0.03% | 275 |
|
|
2019
Q1 | $453K | Buy |
11,807
+4,567
| +63% | +$174K | 0.01% | 519 |
|
|
2018
Q4 | $256K | Buy |
7,240
+300
| +4% | +$10.9K | ﹤0.01% | 568 |
|
|
2018
Q3 | $267K | Buy |
+6,940
| New | +$242K | ﹤0.01% | 629 |
|
Other funds holding BSX
Scotia Capital's BSX Position: Q2 2026 in Review
Scotia Capital increased its Boston Scientific (BSX) stake by 123% in Q2 2026, buying an estimated $3.88M and bringing the position to 129,510 shares worth $5.53M. The position accounts for 0.02% of the portfolio, ranked #292.
Scotia Capital first reported a position in BSX in Q3 2018 and has held it in 30 quarters since. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Scotia Capital held 129,510 shares of Boston Scientific worth $5.53M as of Q2 2026.
- Scotia Capital bought 71,528 Boston Scientific shares in Q2 2026, an estimated $3.88M.
- Boston Scientific made up 0.02% of Scotia Capital's portfolio in Q2 2026, its #292 holding.
- Scotia Capital first reported a position in Boston Scientific in Q3 2018 and has held it in 30 quarters since.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.